Naivek, World's Most Prestigious Keystone Symposia... "Flood of Partnering Meetings on Pulmonary Fibrosis, etc."

[Asia Economy Reporter Jang Hyowon] Naivek, a peptide fusion bio-specialized company, announced research results on treatments for pulmonary fibrosis and liver fibrosis at the Keystone Symposia, renowned as the world's most prestigious conference. The pulmonary fibrosis treatment, currently undergoing global Phase 1 clinical trials, attracted significant attention from industry insiders for its effect of restoring lungs to normal tissue, the company stated on the 21st.

The Keystone Symposia was held over five days starting from the 12th, and Naivek presented its research achievements, including those on pulmonary fibrosis and liver fibrosis, in the session titled "TISSUE FIBROSIS AND REPAIR: MECHANISMS, HUMAN DISEASE AND THERAPIES."

In particular, the pulmonary fibrosis treatment (clinical trial code NP-201) is based on a mechanism that directly binds to receptors generated during the overexpression of inflammation in lung tissue, fundamentally blocking excessive collagen production. This mechanism has drawn attention for its recovery effect that 'reprograms' the lungs into normal tissue.

In the global new drug market, the fibrosis treatment market has recently been rapidly growing, increasing interest in the development of new drugs for fibrosis treatment. This year, Naivek's business partnering meetings were conducted more actively than ever before, which the company explains reflects this market interest.

A Naivek representative said, "Not only potential clients who had previously shown interest but also several institutions including new pharmaceutical companies requested and held meetings with great interest. Follow-up meetings will continue even after the conference ends." He added, "We discussed not only introductions to pulmonary fibrosis (NP-201) and liver fibrosis (NIPEP-NASH) but also the results of animal efficacy studies conducted so far and plans for clinical entry."

He continued, "At Bio USA as well, through a corporate presentation session related to pulmonary fibrosis, we verified our technological superiority externally from global pharmaceutical companies regarding fibrosis. By smoothly conducting related research such as combination therapy and clinical trials, we expect to secure a favorable position in negotiations for joint research or license-out with not only the global pharmaceutical companies currently in discussion but also new companies in the future," he emphasized.